Chembiochem by Waldman, Abraham J. et al.
The cremeomycin biosynthetic gene cluster encodes a pathway 
for diazo formation**
Abraham J. Waldman,
Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford St, Cambridge, 
MA 02138, United States
Yakov Pechersky,
Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford St, Cambridge, 
MA 02138, United States
Peng Wang,
Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford St, Cambridge, 
MA 02138, United States
Jennifer X. Wang, and
Small Molecule Mass Spectrometry Facility, Faculty of Arts and Sciences Division of Science, 
Harvard University, 52 Oxford St, Cambridge, MA 02138, United States
Emily P. Balskus [prof]
Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford St, Cambridge, 
MA 02138, United States
Emily P. Balskus: balskus@chemistry.harvard.edu
Abstract
Diazo groups are found in a range of natural products that possess potent biological activities. 
Despite longstanding interest in these metabolites, diazo group biosynthesis is not well 
understood, in part because of difficulties in identifying specific genes linked to diazo formation. 
Here we describe the discovery of the gene cluster that produces the o-diazoquinone natural 
product cremeomycin and its heterologous expression in Streptomyces lividans. We have used 
stable isotope feeding experiments and in vitro characterization of biosynthetic enzymes to 
decipher the order of events in this pathway and establish that diazo construction involves late-
stage N–N bond formation. This work represents the first successful production of a diazo-
containing metabolite in a heterologous host, experimentally linking a set of genes with diazo 
formation.
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Diazo-containing compounds are exceptionally important reagents with unique reactivity 
that facilitates 1,3-dipolar cycloadditions, carbene insertions, and alkylations. Such broad 
reactivity is useful for applications in both synthetic chemistry and chemical biology.[1] This 
functional group is also found in diverse natural products that have interesting biological 
activity (Figure 1A).[2] The first diazo-containing metabolites discovered were the modified 
α-amino acids azaserine, 6-diazo-5-oxo-L-norleucine (DON), and azotomycin, which were 
isolated from several Streptomyces strains in the 1950s.[3] These L-glutamine mimics gained 
considerable attention for their therapeutic potential and were evaluated clinically.[4] More 
recently, studies of the diazofluorene antitumor antibiotics kinamycin C and lomaiviticin A 
showed that both diazo groups are required for the remarkably enhanced cytotoxicity and 
DNA-cleaving activity of the latter molecule.[5]
Despite sustained interest in diazo-containing natural products from both organic and 
biological chemists, neither the genes nor the enzymatic transformations involved in diazo 
assembly have been characterized experimentally. Understanding the genetic and 
biochemical basis for diazo installation would fill a void in our understanding of enzymatic 
bond constructions and could facilitate biocatalytic and synthetic biology efforts to both 
yield reagents for synthetic chemistry and enable the synthesis of clinically relevant 
molecules.
Insights into diazo biosynthesis have been gained from feeding studies with the metabolites 
kinamycin D and A80915D, a biosynthetic precursor to the pyridazine-containing metabolite 
azamerone. Supplementation of culture media with 15N-labeled inorganic nitrogen sources 
(A80915D) and a 2H-labeled putative intermediate (kinamycin D) has established that diazo 
installation proceeds via N–N bond formation between two nitrogen-containing precursors, 
not through dinitrogen fixation.[6] Recently, our group and others used bioinformatics to 
identify a set of genes in the kinamycin and lomaiviticin gene clusters that we propose are 
responsible for diazo formation.[7] Though the contexts of these genes strongly suggest a 
role in diazo assembly, their functions have not yet been validated experimentally in vivo or 
in vitro. In particular, the inability to reconstitute the biosynthetic pathways of these 
molecules and other diazo containing natural products in heterologous hosts has hindered 
efforts to link specific genes to the construction of this functional group.[6a]
Here we report the discovery and heterologous expression of the biosynthetic gene cluster 
responsible for producing the o-diazoquinone natural product cremeomycin. This work 
represents the first successful heterologous production of a diazo-containing metabolite, thus 
establishing an experimental link between a set of genes and diazo biosynthesis for the first 
time. Using in vitro enzyme characterization and stable isotope feeding studies, we establish 
the order of events in cremeomycin biosynthesis and show that diazo installation requires 
late-stage N–N bond formation. The success of our efforts represents a significant advance 
in our understanding of the genetic basis for diazo assembly and highlights this pathway as 
an excellent system for further mechanistic investigations.
Cremeomycin is a light-sensitive o-diazoquinone with antibacterial and antiproliferative 
effects.[8] It was isolated by the Upjohn Company in 1967 from the soil actinomycete 
Streptomyces cremeus NRRL 3241.[8a] A total synthesis of cremeomycin has also been 
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reported.[9] We used a chemically guided genome mining approach to identify the 
cremeomycin (cre) biosynthetic gene cluster based on the previously-proposed hypothesis 
that 3-amino-4-hydroxybenzoic acid (3,4-AHBA) is a biosynthetic intermediate (Figure 
1B).[8b] This aromatic metabolite is used in multiple natural product biosynthetic pathways 
(Figure S12). In grixazone biosynthesis, 3,4-AHBA is synthesized from the primary 
metabolites dihydroxyacetone phosphate and 4-aspartate semialdehyde by the enzymes GriI 
and GriH.[10] GriI is homologous to class I aldolases, and it catalyzes C–C bond formation 
to generate an intermediate that is cyclized by GriH to afford 3,4-AHBA.
To determine whether S. cremeus possessed these 3,4-AHBA-synthesizing enzymes, we 
used degenerate PCR to amplify putative 3,4-AHBA synthase (griH) homologs from 
genomic DNA.[11] A PCR product with high identity to griH was obtained, suggesting that 
S. cremeus could synthesize 3,4-AHBA. With initial support for our biosynthetic hypothesis, 
we sequenced the genome of S. cremeus. BLAST searches using the griH fragment revealed 
an open reading frame (ORF) encoding a griH homolog (creH) on a 370 kilobase (kb) 
scaffold. In close proximity to this gene were three additional ORFs encoding enzymes with 
predicted functions consistent with a role in cremeomycin assembly: an aldolase homolog 
(creI), a Class A flavin-dependent aromatic monooxygenase (creL), and an S-
adenosylmethionine (SAM)-dependent O-methyltransferase (creN). To determine the cluster 
boundaries we searched the adjacent regions of the scaffold for synteny with the genomes of 
Streptomyces not known to produce cremeomycin. This analysis revealed high conservation 
on either side of an 18 kb region encoding 14 ORFs (creA-creN), which we termed the cre 
gene cluster (Figure 2A & Table S1). In addition to the genes predicted to be responsible for 
3,4-AHBA synthesis and tailoring (creHILN), there were five additional genes encoding 
enzymes that could be involved in diazo formation (creABDEM). The predicted functions of 
some of the encoded enzymes (N-hydroxylation, activation with ATP) are consistent with 
the chemistry required for constructing a diazo group from two separate nitrogen-containing 
metabolites.
We confirmed the link between the cre gene cluster and cremeomycin production through 
heterologous expression in Streptomyces lividans TK-64. The integrative plasmid pCre was 
constructed from a genomic library of S. cremeus and introduced into S. lividans TK-64 via 
standard protoplast transformation. Culturing of this strain in the absence of light in ISP1 
media and analysis of organic extracts of the culture broth using liquid chromatography-
mass spectrometry (LC-MS) and LC-MS/MS revealed the successful production of 
cremeomycin as confirmed by comparison to an authentic standard (Figure 2B, Figures 
S2-3,6). Cremeomycin was not detected in extracts from the wild-type S. lividans TK-64 
strain. These results strongly suggest that the cre cluster contains all of the genes necessary 
for cremeomycin biosynthesis, providing the first experimental link between a set of genes 
and diazo biosynthesis. Importantly, the S. lividans TK-64 genome does not contain either a 
cre-type or lom-type putative diazo gene cassette, affording further confirmation that this 
reactivity is mediated entirely by the cre gene cluster. The success of this heterologous 
expression therefore narrows the candidate genes encoding diazo-forming enzymes to 
creABDEM, marking a critical first step towards future mechanistic characterization.
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We also identified a second metabolite produced by both S. cremeus and S. lividans 
TK-64::cre, 2-hydroxy-4-methoxybenzoic acid (2,4-HMBA). The compound was initially 
discovered during efforts to isolate cremeomycin from S. cremeus, and its identity was 
established using NMR and MS. Extracts from S. lividans TK-64::cre contained 2,4-HMBA 
as confirmed by LC-MS and LC-MS/MS comparison with a commercial standard (Figure 
2B, Figures S4-5). This compound was not present in extracts of wild-type S. lividans 
TK-64. We hypothesized that this product results from o-diazoquinone reduction. Indeed, 
cremeomycin incubated in sterile culture media in the absence of light decomposes to 
produce 2,4-HMBA over several hours to days (Figure S1).
Having confirmed the involvement of the cre cluster in cremeomycin biosynthesis, we next 
elucidated the order of events in the pathway. We first investigated the functions of CreH/
CreI and the role of 3,4-AHBA as a biosynthetic intermediate. We cloned creH and creI 
together into the expression plasmid pET-29b, which was transformed into Escherichia coli 
Tuner cells. This strain produced 3,4-AHBA and its N-acetylated derivative 3-acetamido-4-
hydroxybenzoic acid, (3,4-NAcHBA) as minor and major products, respectively (Figure 
3A). Metabolite identities were confirmed by comparison to authentic standards. These 
molecules were not detected in an E. coli Tuner strain harboring an empty pET-29b vector. 
Production of 3,4-AHBA and its N-acetylated derivative is consistent with previous studies 
of griH and griI[10b] and the known arylamine N-acetyltransferase activity of E. coli.[12] We 
further established the role of 3,4-AHBA in cremeomycin assembly by feeding 15N-labeled 
3,4-AHBA to S. cremeus. Analysis of the isotopic pattern of cremeomycin revealed 40% 
incorporation of the 15N label, confirming this metabolite is on pathway (Figure 3B & 
Figure S7). These results also demonstrated that diazo formation proceeds via N–N bond 
formation in agreement with other diazo-containing natural product biosynthetic 
pathways.[6]
Conversion of 3,4-AHBA to cremeomycin must involve hydroxylation at C2, methylation of 
the C4 hydroxyl group, and diazotization of the C3 amino group. We obtained information 
about the potential order of these events from the 15N-3,4-AHBA feeding experiment. The 
LC-MS data contained a 15N-labeled metabolite with a mass matching that of 3-amino-2-
hydroxy-4-methoxybenzoic acid (3,2,4-AHMBA). This molecule could arise from 3,4-
AHBA via the actions of monooxygenase CreL and O-methyltransferase CreN. We 
synthesized and fed a 15N-labeled version of this molecule to S. cremeus. Analysis of 
extracts by LC-MS revealed 86% incorporation of the 15N label into cremeomycin (Figure 
3B & Figure S8), confirming that 3,2,4-AHMBA is a biosynthetic intermediate. These data 
further demonstrated that hydroxylation and O-methylation precede diazotization in 
cremeomycin biosynthesis.
We determined the order of hydroxylation and O-methylation in 3,2,4-AHMBA biosynthesis 
by characterizing the activities of recombinant CreL and CreN in vitro. Both genes were 
cloned and expressed in E. coli as C-His6 fusions. CreL-C-His6 purified with bound FAD as 
determined by LC-MS/MS (Figure S10). Incubation of O-methyltransferase CreN with 
SAM and either 3,4-AHBA or 3-amino-2,4-dihydroxybenzoic acid (3,2,4-ADBA) and 
analysis using high performance liquid chromatography (HPLC) showed CreN- and SAM-
dependent conversion of both molecules to their respective C4 O-methylated products 
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(Figure S11). The lack of a significant difference in the qualitative rates of O-methylation 
prevented any insight into the order of events. Conversely, when monooxygenase CreL was 
incubated with FAD, NADPH, and either 3,4-AHBA or 3-amino-4-methoxybenzoic acid 
(3,4-AMBA), a new peak was observed by HPLC only in the presence of 3,4-AHBA (Figure 
4A). This product was confirmed to be 3,2,4-ADBA by comparison to an authentic standard 
and its formation was dependent on CreL and NADPH. No conversion of 3,4-AMBA to 
3,2,4-AHMBA was observed under any conditions tested. The substrate specificity of CreL 
revealed that hydroxylation precedes O-methylation in the transformation of 3,4-AHBA to 
3,2,4-AHMBA.
In summary, our results establish the order of events in cremeomycin biosynthesis up to the 
point of diazotization of 3,2,4-AHMBA, which must be catalyzed by one or more of the 
remaining enzymes (CreABDEM) (Figure 4B). Several of the annotated functions of these 
enzymes (N-hydroxylation, activation with ATP) are consistent with this assignment, as 
similar enzymes have been proposed to be involved in the biosynthesis of piperazic acid, a 
N–N bond containing non-proteinogenic amino acid that is a building block in nonribosomal 
peptide biosynthesis.[13] Interestingly, CreABDEM are not related to the proposed diazo-
forming enzymes from the lomaiviticin and kinamycin pathways. Neither set of putative 
diazo-forming genes is found in its entirety in the azamerone biosynthetic gene cluster, 
which contains only a CreM homolog.[6a] Intriguingly, genes encoding CreD and CreE are 
clustered elsewhere in the genome of the azamerone producer, Streptomyces sp. CNQ-525. 
The distinct localization of these genes could explain the lack of azamerone production in 
attempted heterologous expressions.[6a] The presence of distinct biosynthetic machinery in 
different diazo-synthesizing gene clusters may reflect multiple evolutionary solutions to the 
problem of installing this reactive functional group. Understanding these different pathways 
could prove beneficial in efforts to access diazo groups using biocatalysis and synthetic 
biology. Our characterization of the early steps of cremeomycin biosynthesis now sets the 
stage for elucidating the enzymatic chemistry of diazo installation. Addressing this 
important future challenge should enhance our understanding of how Nature generates 
reactive functionality and reveal new tools for chemical production.
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Cremeomycin is an o-diazoquinone natural product. A) Selected diazo-containing secondary 
metabolites. B) Biosynthetic hypothesis for cremeomycin assembly.
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Identification and heterologous expression of the cremeomycin (cre) biosynthetic gene 
cluster. A) The cre biosynthetic gene cluster. Refer to SI for complete annotation. B) 
Heterologous expression of the cre cluster in S. lividans TK-64 affords production of 
cremeomycin and 2,4-HMBA. Extracted ion chromatograms (EIC) are shown.
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3,4-AHBA and 3,2,4-AHMBA are intermediates in cremeomycin biosynthesis. A) 
Heterologous expression of creH and creI in E. coli affords 3,4-AHBA and 3,4-NAcHBA. 
B) Stable isotope feeding experiments show incorporation of 15N-labeled 3,4-AHBA and 
3,2,4-AHMBA into cremeomycin.
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Hydroxylation precedes methylation in the early stages of cremeomycin biosynthesis. A) 
HPLC assays of flavin-dependent monooxygenase CreL (254 nm) B) Hypothesis for the 
biosynthesis of cremeomycin from 3,4-AHBA.
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